Global Decentralised Clinical Trials Market Size Study, by Study Design (Interventional, Observational, Expanded Access), by Indication (Oncology, Cardiovascular, Immunology, Respiratory, Others), by Component (Mobile Healthcare, Telemedicine, Wearable Devices, Web-based Technology, Others), by End-users (Pharmaceutical and Biopharmaceutical Companies, CROs, Others) and Regional Forecasts 2022-2032
Global Decentralised Clinical Trials Market is valued at approximately USD 9.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.40% over the forecast period 2024-2032. Decentralised Clinical Trials (DCTs) has revolutionized the landscape of clinical research, offering a paradigm shift in how trials are conducted. This innovative approach leverages digital health technologies, enabling remote monitoring and data collection, thus enhancing participant convenience and broadening patient diversity. The driving force behind this market surge includes the imperative to accelerate drug development timelines, mitigate costs, and increase the accessibility of diverse treatments to among large number of patients.
The globalization of clinical trials underscores a transformative era in the healthcare sector, driven by an extensive reach across various geographies. Pharmaceutical and biotech companies are heavily investing in these trials to garner comprehensive data from diverse demographic groups. This inclusivity in clinical trials fosters a deeper understanding of treatment efficacies across different genetic and socio-economic backgrounds, unveiling critical insights into potential side effects and drug responses. Moreover, regulatory harmonization has streamlined approval processes across multiple countries, reducing redundant efforts and expediting the introduction of breakthrough therapies to the market. However, concerns regarding data privacy and security and regulatory compliance are going to impede the overall demand for the market during the forecast period 2024-2032.
The key regions considered for the Global Decentralised Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the dominating among regional market in terms of revenue owing to factors such as advanced healthcare infrastructure and the presence of major pharmaceutical companies. Regulatory bodies such as the FDA have been increasingly supportive of DCTs, providing guidelines and frameworks that facilitate the adoption of these trials. This regulatory environment encourages pharmaceutical companies to explore decentralized models. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.
Major market players included in this report are:
ICON plc
Medpace Holdings, Inc.
Parexel International Corporation
PPD, Inc.
Covance Inc.
LabCorp Drug Development
PRA Health Sciences
Syneos Health
IQVIA Holdings Inc.
Charles River Laboratories International, Inc
The detailed segments and sub-segment of the market are explained below:
By Study Design
Interventional
Observational
Expanded Access
By Indication
Oncology
Cardiovascular
Immunology
Respiratory
Others
By Component
Mobile Healthcare
Telemedicine
Wearable Devices
Web-based Technology
Others
By End-users
Pharmaceutical and Biopharmaceutical Companies
CROs
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
The globalization of clinical trials underscores a transformative era in the healthcare sector, driven by an extensive reach across various geographies. Pharmaceutical and biotech companies are heavily investing in these trials to garner comprehensive data from diverse demographic groups. This inclusivity in clinical trials fosters a deeper understanding of treatment efficacies across different genetic and socio-economic backgrounds, unveiling critical insights into potential side effects and drug responses. Moreover, regulatory harmonization has streamlined approval processes across multiple countries, reducing redundant efforts and expediting the introduction of breakthrough therapies to the market. However, concerns regarding data privacy and security and regulatory compliance are going to impede the overall demand for the market during the forecast period 2024-2032.
The key regions considered for the Global Decentralised Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the dominating among regional market in terms of revenue owing to factors such as advanced healthcare infrastructure and the presence of major pharmaceutical companies. Regulatory bodies such as the FDA have been increasingly supportive of DCTs, providing guidelines and frameworks that facilitate the adoption of these trials. This regulatory environment encourages pharmaceutical companies to explore decentralized models. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.
Major market players included in this report are:
ICON plc
Medpace Holdings, Inc.
Parexel International Corporation
PPD, Inc.
Covance Inc.
LabCorp Drug Development
PRA Health Sciences
Syneos Health
IQVIA Holdings Inc.
Charles River Laboratories International, Inc
The detailed segments and sub-segment of the market are explained below:
By Study Design
Interventional
Observational
Expanded Access
By Indication
Oncology
Cardiovascular
Immunology
Respiratory
Others
By Component
Mobile Healthcare
Telemedicine
Wearable Devices
Web-based Technology
Others
By End-users
Pharmaceutical and Biopharmaceutical Companies
CROs
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
CHAPTER 1. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET EXECUTIVE SUMMARY
1.1. Global Decentralised Clinical Trials Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Study Design
1.3.2. By Indication
1.3.3. By Component
1.3.4. By End-users
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Accelerated Drug Development
3.1.2. Cost Reduction
3.1.3. Access to Diverse Populations
3.2. Market Challenges
3.2.1. Data Privacy and Security Concerns
3.2.2. Regulatory Compliance
3.3. Market Opportunities
3.3.1. Technological Advancements
3.3.2. Expansion in Emerging Markets
3.3.3. Increased Collaboration and Data Exchange
CHAPTER 4. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY STUDY DESIGN 2022-2032
5.1. Segment Dashboard
5.2. Global Decentralised Clinical Trials Market: Study Design Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Interventional
5.2.2. Observational
5.2.3. Expanded Access
CHAPTER 6. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
6.1. Segment Dashboard
6.2. Global Decentralised Clinical Trials Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oncology
6.2.2. Cardiovascular
6.2.3. Immunology
6.2.4. Respiratory
6.2.5. Others
CHAPTER 7. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY COMPONENT 2022-2032
7.1. Segment Dashboard
7.2. Global Decentralised Clinical Trials Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Mobile Healthcare
7.2.2. Telemedicine
7.2.3. Wearable Devices
7.2.4. Web-based Technology
7.2.5. Others
CHAPTER 8. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY END-USERS 2022-2032
8.1. Segment Dashboard
8.2. Global Decentralised Clinical Trials Market: End-users Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Pharmaceutical and Biopharmaceutical Companies
8.2.2. CROs
8.2.3. Others
CHAPTER 9. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY REGION 2022-2032
9.1. North America Decentralised Clinical Trials Market
9.1.1. U.S. Decentralised Clinical Trials Market
9.1.1.1. Study Design breakdown size & forecasts, 2022-2032
9.1.1.2. Indication breakdown size & forecasts, 2022-2032
9.1.1.3. Component breakdown size & forecasts, 2022-2032
9.1.1.4. End-users breakdown size & forecasts, 2022-2032
9.1.2. Canada Decentralised Clinical Trials Market
9.1.2.1. Study Design breakdown size & forecasts, 2022-2032
9.1.2.2. Indication breakdown size & forecasts, 2022-2032
9.1.2.3. Component breakdown size & forecasts, 2022-2032
9.1.2.4. End-users breakdown size & forecasts, 2022-2032
9.2. Europe Decentralised Clinical Trials Market
9.2.1. U.K. Decentralised Clinical Trials Market
9.2.1.1. Study Design breakdown size & forecasts, 2022-2032
9.2.1.2. Indication breakdown size & forecasts, 2022-2032
9.2.1.3. Component breakdown size & forecasts, 2022-2032
9.2.1.4. End-users breakdown size & forecasts, 2022-2032
9.2.2. Germany Decentralised Clinical Trials Market
9.2.2.1. Study Design breakdown size & forecasts, 2022-2032
9.2.2.2. Indication breakdown size & forecasts, 2022-2032
9.2.2.3. Component breakdown size & forecasts, 2022-2032
9.2.2.4. End-users breakdown size & forecasts, 2022-2032
9.2.3. France Decentralised Clinical Trials Market
9.2.3.1. Study Design breakdown size & forecasts, 2022-2032
9.2.3.2. Indication breakdown size & forecasts, 2022-2032
9.2.3.3. Component breakdown size & forecasts, 2022-2032
9.2.3.4. End-users breakdown size & forecasts, 2022-2032
9.2.4. Spain Decentralised Clinical Trials Market
9.2.4.1. Study Design breakdown size & forecasts, 2022-2032
9.2.4.2. Indication breakdown size & forecasts, 2022-2032
9.2.4.3. Component breakdown size & forecasts, 2022-2032
9.2.4.4. End-users breakdown size & forecasts, 2022-2032
9.2.5. Italy Decentralised Clinical Trials Market
9.2.5.1. Study Design breakdown size & forecasts, 2022-2032
9.2.5.2. Indication breakdown size & forecasts, 2022-2032
9.2.5.3. Component breakdown size & forecasts, 2022-2032
9.2.5.4. End-users breakdown size & forecasts, 2022-2032
9.2.6. Rest of Europe Decentralised Clinical Trials Market
9.2.6.1. Study Design breakdown size & forecasts, 2022-2032
9.2.6.2. Indication breakdown size & forecasts, 2022-2032
9.2.6.3. Component breakdown size & forecasts, 2022-2032
9.2.6.4. End-users breakdown size & forecasts, 2022-2032
9.3. Asia-Pacific Decentralised Clinical Trials Market
9.3.1. China Decentralised Clinical Trials Market
9.3.1.1. Study Design breakdown size & forecasts, 2022-2032
9.3.1.2. Indication breakdown size & forecasts, 2022-2032
9.3.1.3. Component breakdown size & forecasts, 2022-2032
9.3.1.4. End-users breakdown size & forecasts, 2022-2032
9.3.2. India Decentralised Clinical Trials Market
9.3.2.1. Study Design breakdown size & forecasts, 2022-2032
9.3.2.2. Indication breakdown size & forecasts, 2022-2032
9.3.2.3. Component breakdown size & forecasts, 2022-2032
9.3.2.4. End-users breakdown size & forecasts, 2022-2032
9.3.3. Japan Decentralised Clinical Trials Market
9.3.3.1. Study Design breakdown size & forecasts, 2022-2032
9.3.3.2. Indication breakdown size & forecasts, 2022-2032
9.3.3.3. Component breakdown size & forecasts, 2022-2032
9.3.3.4. End-users breakdown size & forecasts, 2022-2032
9.3.4. Australia Decentralised Clinical Trials Market
9.3.4.1. Study Design breakdown size & forecasts, 2022-2032
9.3.4.2. Indication breakdown size & forecasts, 2022-2032
9.3.4.3. Component breakdown size & forecasts, 2022-2032
9.3.4.4. End-users breakdown size & forecasts, 2022-2032
9.3.5. South Korea Decentralised Clinical Trials Market
9.3.5.1. Study Design breakdown size & forecasts, 2022-2032
9.3.5.2. Indication breakdown size & forecasts, 2022-2032
9.3.5.3. Component breakdown size & forecasts, 2022-2032
9.3.5.4. End-users breakdown size & forecasts, 2022-2032
9.3.6. Rest of Asia Pacific Decentralised Clinical Trials Market
9.3.6.1. Study Design breakdown size & forecasts, 2022-2032
9.3.6.2. Indication breakdown size & forecasts, 2022-2032
9.3.6.3. Component breakdown size & forecasts, 2022-2032
9.3.6.4. End-users breakdown size & forecasts, 2022-2032
9.4. Latin America Decentralised Clinical Trials Market
9.4.1. Brazil Decentralised Clinical Trials Market
9.4.1.1. Study Design breakdown size & forecasts, 2022-2032
9.4.1.2. Indication breakdown size & forecasts, 2022-2032
9.4.1.3. Component breakdown size & forecasts, 2022-2032
9.4.1.4. End-users breakdown size & forecasts, 2022-2032
9.4.2. Mexico Decentralised Clinical Trials Market
9.4.2.1. Study Design breakdown size & forecasts, 2022-2032
9.4.2.2. Indication breakdown size & forecasts, 2022-2032
9.4.2.3. Component breakdown size & forecasts, 2022-2032
9.4.2.4. End-users breakdown size & forecasts, 2022-2032
9.4.3. Rest of Latin America Decentralised Clinical Trials Market
9.4.3.1. Study Design breakdown size & forecasts, 2022-2032
9.4.3.2. Indication breakdown size & forecasts, 2022-2032
9.4.3.3. Component breakdown size & forecasts, 2022-2032
9.4.3.4. End-users breakdown size & forecasts, 2022-2032
9.5. Middle East & Africa Decentralised Clinical Trials Market
9.5.1. Saudi Arabia Decentralised Clinical Trials Market
9.5.1.1. Study Design breakdown size & forecasts, 2022-2032
9.5.1.2. Indication breakdown size & forecasts, 2022-2032
9.5.1.3. Component breakdown size & forecasts, 2022-2032
9.5.1.4. End-users breakdown size & forecasts, 2022-2032
9.5.2. South Africa Decentralised Clinical Trials Market
9.5.2.1. Study Design breakdown size & forecasts, 2022-2032
9.5.2.2. Indication breakdown size & forecasts, 2022-2032
9.5.2.3. Component breakdown size & forecasts, 2022-2032
9.5.2.4. End-users breakdown size & forecasts, 2022-2032
9.5.3. Rest of Middle East & Africa Decentralised Clinical Trials Market
9.5.3.1. Study Design breakdown size & forecasts, 2022-2032
9.5.3.2. Indication breakdown size & forecasts, 2022-2032
9.5.3.3. Component breakdown size & forecasts, 2022-2032
9.5.3.4. End-users breakdown size & forecasts, 2022-2032
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. ICON plc
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Medpace Holdings, Inc.
10.3.3. Parexel International Corporation
10.3.4. PPD, Inc.
10.3.5. Covance Inc.
10.3.6. LabCorp Drug Development
10.3.7. PRA Health Sciences
10.3.8. Syneos Health
10.3.9. IQVIA Holdings Inc.
10.3.10. Charles River Laboratories International, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Decentralised Clinical Trials Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Study Design
1.3.2. By Indication
1.3.3. By Component
1.3.4. By End-users
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Accelerated Drug Development
3.1.2. Cost Reduction
3.1.3. Access to Diverse Populations
3.2. Market Challenges
3.2.1. Data Privacy and Security Concerns
3.2.2. Regulatory Compliance
3.3. Market Opportunities
3.3.1. Technological Advancements
3.3.2. Expansion in Emerging Markets
3.3.3. Increased Collaboration and Data Exchange
CHAPTER 4. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY STUDY DESIGN 2022-2032
5.1. Segment Dashboard
5.2. Global Decentralised Clinical Trials Market: Study Design Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Interventional
5.2.2. Observational
5.2.3. Expanded Access
CHAPTER 6. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
6.1. Segment Dashboard
6.2. Global Decentralised Clinical Trials Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oncology
6.2.2. Cardiovascular
6.2.3. Immunology
6.2.4. Respiratory
6.2.5. Others
CHAPTER 7. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY COMPONENT 2022-2032
7.1. Segment Dashboard
7.2. Global Decentralised Clinical Trials Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Mobile Healthcare
7.2.2. Telemedicine
7.2.3. Wearable Devices
7.2.4. Web-based Technology
7.2.5. Others
CHAPTER 8. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY END-USERS 2022-2032
8.1. Segment Dashboard
8.2. Global Decentralised Clinical Trials Market: End-users Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Pharmaceutical and Biopharmaceutical Companies
8.2.2. CROs
8.2.3. Others
CHAPTER 9. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY REGION 2022-2032
9.1. North America Decentralised Clinical Trials Market
9.1.1. U.S. Decentralised Clinical Trials Market
9.1.1.1. Study Design breakdown size & forecasts, 2022-2032
9.1.1.2. Indication breakdown size & forecasts, 2022-2032
9.1.1.3. Component breakdown size & forecasts, 2022-2032
9.1.1.4. End-users breakdown size & forecasts, 2022-2032
9.1.2. Canada Decentralised Clinical Trials Market
9.1.2.1. Study Design breakdown size & forecasts, 2022-2032
9.1.2.2. Indication breakdown size & forecasts, 2022-2032
9.1.2.3. Component breakdown size & forecasts, 2022-2032
9.1.2.4. End-users breakdown size & forecasts, 2022-2032
9.2. Europe Decentralised Clinical Trials Market
9.2.1. U.K. Decentralised Clinical Trials Market
9.2.1.1. Study Design breakdown size & forecasts, 2022-2032
9.2.1.2. Indication breakdown size & forecasts, 2022-2032
9.2.1.3. Component breakdown size & forecasts, 2022-2032
9.2.1.4. End-users breakdown size & forecasts, 2022-2032
9.2.2. Germany Decentralised Clinical Trials Market
9.2.2.1. Study Design breakdown size & forecasts, 2022-2032
9.2.2.2. Indication breakdown size & forecasts, 2022-2032
9.2.2.3. Component breakdown size & forecasts, 2022-2032
9.2.2.4. End-users breakdown size & forecasts, 2022-2032
9.2.3. France Decentralised Clinical Trials Market
9.2.3.1. Study Design breakdown size & forecasts, 2022-2032
9.2.3.2. Indication breakdown size & forecasts, 2022-2032
9.2.3.3. Component breakdown size & forecasts, 2022-2032
9.2.3.4. End-users breakdown size & forecasts, 2022-2032
9.2.4. Spain Decentralised Clinical Trials Market
9.2.4.1. Study Design breakdown size & forecasts, 2022-2032
9.2.4.2. Indication breakdown size & forecasts, 2022-2032
9.2.4.3. Component breakdown size & forecasts, 2022-2032
9.2.4.4. End-users breakdown size & forecasts, 2022-2032
9.2.5. Italy Decentralised Clinical Trials Market
9.2.5.1. Study Design breakdown size & forecasts, 2022-2032
9.2.5.2. Indication breakdown size & forecasts, 2022-2032
9.2.5.3. Component breakdown size & forecasts, 2022-2032
9.2.5.4. End-users breakdown size & forecasts, 2022-2032
9.2.6. Rest of Europe Decentralised Clinical Trials Market
9.2.6.1. Study Design breakdown size & forecasts, 2022-2032
9.2.6.2. Indication breakdown size & forecasts, 2022-2032
9.2.6.3. Component breakdown size & forecasts, 2022-2032
9.2.6.4. End-users breakdown size & forecasts, 2022-2032
9.3. Asia-Pacific Decentralised Clinical Trials Market
9.3.1. China Decentralised Clinical Trials Market
9.3.1.1. Study Design breakdown size & forecasts, 2022-2032
9.3.1.2. Indication breakdown size & forecasts, 2022-2032
9.3.1.3. Component breakdown size & forecasts, 2022-2032
9.3.1.4. End-users breakdown size & forecasts, 2022-2032
9.3.2. India Decentralised Clinical Trials Market
9.3.2.1. Study Design breakdown size & forecasts, 2022-2032
9.3.2.2. Indication breakdown size & forecasts, 2022-2032
9.3.2.3. Component breakdown size & forecasts, 2022-2032
9.3.2.4. End-users breakdown size & forecasts, 2022-2032
9.3.3. Japan Decentralised Clinical Trials Market
9.3.3.1. Study Design breakdown size & forecasts, 2022-2032
9.3.3.2. Indication breakdown size & forecasts, 2022-2032
9.3.3.3. Component breakdown size & forecasts, 2022-2032
9.3.3.4. End-users breakdown size & forecasts, 2022-2032
9.3.4. Australia Decentralised Clinical Trials Market
9.3.4.1. Study Design breakdown size & forecasts, 2022-2032
9.3.4.2. Indication breakdown size & forecasts, 2022-2032
9.3.4.3. Component breakdown size & forecasts, 2022-2032
9.3.4.4. End-users breakdown size & forecasts, 2022-2032
9.3.5. South Korea Decentralised Clinical Trials Market
9.3.5.1. Study Design breakdown size & forecasts, 2022-2032
9.3.5.2. Indication breakdown size & forecasts, 2022-2032
9.3.5.3. Component breakdown size & forecasts, 2022-2032
9.3.5.4. End-users breakdown size & forecasts, 2022-2032
9.3.6. Rest of Asia Pacific Decentralised Clinical Trials Market
9.3.6.1. Study Design breakdown size & forecasts, 2022-2032
9.3.6.2. Indication breakdown size & forecasts, 2022-2032
9.3.6.3. Component breakdown size & forecasts, 2022-2032
9.3.6.4. End-users breakdown size & forecasts, 2022-2032
9.4. Latin America Decentralised Clinical Trials Market
9.4.1. Brazil Decentralised Clinical Trials Market
9.4.1.1. Study Design breakdown size & forecasts, 2022-2032
9.4.1.2. Indication breakdown size & forecasts, 2022-2032
9.4.1.3. Component breakdown size & forecasts, 2022-2032
9.4.1.4. End-users breakdown size & forecasts, 2022-2032
9.4.2. Mexico Decentralised Clinical Trials Market
9.4.2.1. Study Design breakdown size & forecasts, 2022-2032
9.4.2.2. Indication breakdown size & forecasts, 2022-2032
9.4.2.3. Component breakdown size & forecasts, 2022-2032
9.4.2.4. End-users breakdown size & forecasts, 2022-2032
9.4.3. Rest of Latin America Decentralised Clinical Trials Market
9.4.3.1. Study Design breakdown size & forecasts, 2022-2032
9.4.3.2. Indication breakdown size & forecasts, 2022-2032
9.4.3.3. Component breakdown size & forecasts, 2022-2032
9.4.3.4. End-users breakdown size & forecasts, 2022-2032
9.5. Middle East & Africa Decentralised Clinical Trials Market
9.5.1. Saudi Arabia Decentralised Clinical Trials Market
9.5.1.1. Study Design breakdown size & forecasts, 2022-2032
9.5.1.2. Indication breakdown size & forecasts, 2022-2032
9.5.1.3. Component breakdown size & forecasts, 2022-2032
9.5.1.4. End-users breakdown size & forecasts, 2022-2032
9.5.2. South Africa Decentralised Clinical Trials Market
9.5.2.1. Study Design breakdown size & forecasts, 2022-2032
9.5.2.2. Indication breakdown size & forecasts, 2022-2032
9.5.2.3. Component breakdown size & forecasts, 2022-2032
9.5.2.4. End-users breakdown size & forecasts, 2022-2032
9.5.3. Rest of Middle East & Africa Decentralised Clinical Trials Market
9.5.3.1. Study Design breakdown size & forecasts, 2022-2032
9.5.3.2. Indication breakdown size & forecasts, 2022-2032
9.5.3.3. Component breakdown size & forecasts, 2022-2032
9.5.3.4. End-users breakdown size & forecasts, 2022-2032
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. ICON plc
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Medpace Holdings, Inc.
10.3.3. Parexel International Corporation
10.3.4. PPD, Inc.
10.3.5. Covance Inc.
10.3.6. LabCorp Drug Development
10.3.7. PRA Health Sciences
10.3.8. Syneos Health
10.3.9. IQVIA Holdings Inc.
10.3.10. Charles River Laboratories International, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Decentralised Clinical Trials Market, Report Scope
TABLE 2. Global Decentralised Clinical Trials Market Estimates & Forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Decentralised Clinical Trials Market Estimates & Forecasts by Study Design 2022-2032 (USD Billion)
TABLE 4. Global Decentralised Clinical Trials Market Estimates & Forecasts by Indication 2022-2032 (USD Billion)
TABLE 5. Global Decentralised Clinical Trials Market Estimates & Forecasts by Component 2022-2032 (USD Billion)
TABLE 6. Global Decentralised Clinical Trials Market Estimates & Forecasts by End-users 2022-2032 (USD Billion)
TABLE 7. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Decentralised Clinical Trials Market Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 17. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 18. Canada Decentralised Clinical Trials Market Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 20. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
…..
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable
TABLE 1. Global Decentralised Clinical Trials Market, Report Scope
TABLE 2. Global Decentralised Clinical Trials Market Estimates & Forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Decentralised Clinical Trials Market Estimates & Forecasts by Study Design 2022-2032 (USD Billion)
TABLE 4. Global Decentralised Clinical Trials Market Estimates & Forecasts by Indication 2022-2032 (USD Billion)
TABLE 5. Global Decentralised Clinical Trials Market Estimates & Forecasts by Component 2022-2032 (USD Billion)
TABLE 6. Global Decentralised Clinical Trials Market Estimates & Forecasts by End-users 2022-2032 (USD Billion)
TABLE 7. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Decentralised Clinical Trials Market Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 17. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 18. Canada Decentralised Clinical Trials Market Estimates & Forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
TABLE 20. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)
…..
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable
LIST OF FIGURES
FIG 1. Global Decentralised Clinical Trials Market, Research Methodology
FIG 2. Global Decentralised Clinical Trials Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods.
FIG 4. Global Decentralised Clinical Trials Market, Key Trends 2023
FIG 5. Global Decentralised Clinical Trials Market, Growth Prospects 2022-2032
FIG 6. Global Decentralised Clinical Trials Market, Porter’s 5 Force Model
FIG 7. Global Decentralised Clinical Trials Market, PESTEL Analysis
FIG 8. Global Decentralised Clinical Trials Market, Value Chain Analysis
FIG 9. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 10. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 11. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 12. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 13. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 14. Global Decentralised Clinical Trials Market, Regional Snapshot 2022 & 2032
FIG 15. North America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 16. Europe Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 17. Asia Pacific Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 18. Latin America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 20. Global Decentralised Clinical Trials Market, Company Market Share Analysis (2023)
FIG 1. Global Decentralised Clinical Trials Market, Research Methodology
FIG 2. Global Decentralised Clinical Trials Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods.
FIG 4. Global Decentralised Clinical Trials Market, Key Trends 2023
FIG 5. Global Decentralised Clinical Trials Market, Growth Prospects 2022-2032
FIG 6. Global Decentralised Clinical Trials Market, Porter’s 5 Force Model
FIG 7. Global Decentralised Clinical Trials Market, PESTEL Analysis
FIG 8. Global Decentralised Clinical Trials Market, Value Chain Analysis
FIG 9. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 10. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 11. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 12. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 13. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
FIG 14. Global Decentralised Clinical Trials Market, Regional Snapshot 2022 & 2032
FIG 15. North America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 16. Europe Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 17. Asia Pacific Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 18. Latin America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
FIG 20. Global Decentralised Clinical Trials Market, Company Market Share Analysis (2023)
